Though PET with 68Ga-PSMA was originally utilized to evaluate biochemical recurrence of prostate cancer, increased uptake of PSMA ligand has been reported in a variety of non-prostatic diseases, including inflammatory processes, bone lesions, benign tumors, and malignant neoplasms [45]. Here, FOLH1 is linked to benign neoplasm.